Diving Into Therapeutic Decision-Making in Later-Line CLL

Nicole Lamanna, MD, discusses pirtobrutinib decision-making in the relapsed/refractory CLL setting and ongoing earlier-line research with the agent.

Nicole Lamanna, MD, shares key considerations for the use of pirtobrutinib in the management of chronic lymphocytic leukemia.

Dr Lamanna discusses how disease progression, treatment intolerance, and prior therapy exposure inform the decision to initiate pirtobrutinib in CLL.